• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    6/2/23 1:31:42 PM ET
    $BLCM
    $CNSP
    $HLTH
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLCM alert in real time by email

    Gainers

    • Minerva Surgical (NASDAQ:UTRS) shares increased by 111.8% to $0.42 during Friday's regular session. As of 13:30 EST, Minerva Surgical's stock is trading at a volume of 85.0 million, which is 3814.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $74.9 million.
    • CNS Pharma (NASDAQ:CNSP) stock rose 20.44% to $2.18. CNS Pharma's stock is trading at a volume of 1.6 million shares as of 13:30 EST. This is 48.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.0 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) stock moved upwards by 18.57% to $17.62. As of 13:30 EST, this security is trading at a volume of 196.9K shares, making up 33.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $41.3 million.
    • Praxis Precision Medicine (NASDAQ:PRAX) stock moved upwards by 18.57% to $1.04. As of 13:30 EST, this security is trading at a volume of 1.3 million shares, making up 82.8% of its average full-day volume over the last 100 days. The company's market cap stands at $64.5 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) shares rose 18.53% to $0.41. Trading volume for this security as of 13:30 EST is 91.6K, which is 207.8% of its average full-day volume over the last 100 days. The company's market cap stands at $10.8 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCCP) shares increased by 18.23% to $12.97.

    Losers

    • Bellicum Pharmaceuticals (NASDAQ:BLCM) shares declined by 63.7% to $0.25 during Friday's regular session. The market value of their outstanding shares is at $2.3 million.
    • Kiora Pharmaceuticals (NASDAQ:KPRX) shares fell 49.85% to $0.83. As of 13:30 EST, this security is trading at a volume of 3.6 million shares, making up 5902.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.6 million.
    • Oncorus (NASDAQ:ONCR) shares fell 40.99% to $0.11. Trading volume for this security as of 13:30 EST is 3.6 million, which is 1320.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.7 million.
    • Sight Sciences (NASDAQ:SGHT) stock decreased by 19.15% to $7.73. Sight Sciences's stock is trading at a volume of 273.4K shares as of 13:30 EST. This is 248.7% of its average full-day volume over the last 100 days. The company's market cap stands at $374.5 million.
    • Cue Health (NASDAQ:HLTH) shares declined by 16.0% to $0.6. Trading volume for this security as of 13:30 EST is 1.0 million, which is 252.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $91.0 million.
    • Trxade Health (NASDAQ:MEDS) stock declined by 15.28% to $0.33. Trading volume for Trxade Health's stock is 376.2K as of 13:30 EST. This is 93.4% of its average full-day volume over the last 100 days. The company's market cap stands at $3.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BLCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCM
    $CNSP
    $HLTH
    $KALA

    CompanyDatePrice TargetRatingAnalyst
    Praxis Precision Medicines Inc.
    $PRAX
    2/24/2026$500.00Outperform
    Wolfe Research
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Praxis Precision Medicines Inc.
    $PRAX
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    Praxis Precision Medicines Inc.
    $PRAX
    11/19/2025$424.00Buy
    BTIG Research
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $BLCM
    $CNSP
    $HLTH
    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Daniels Eric Joseph covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.90% to 26,137 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/6/26 2:03:53 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Strem Brian M. covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.52% to 45,865 units (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/6/26 2:03:29 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Technology Officer Faulkner Eric

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:29 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CNSP
    $HLTH
    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CNSP
    $HLTH
    $KALA
    SEC Filings

    View All

    SEC Form 10-K filed by Sight Sciences Inc.

    10-K - Sight Sciences, Inc. (0001531177) (Filer)

    3/4/26 4:19:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    3/4/26 4:08:05 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    KALA BIO Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - KALA BIO, Inc. (0001479419) (Filer)

    3/4/26 9:16:52 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CNSP
    $HLTH
    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

    3/4/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

    Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of $926 million as of December 31, 2025 and net proceeds of $621 million from January 2026 public offering fund operations into 2028Conference call today, February 19, 2026 at 8:00 am E.T. BOSTON, Feb. 19, 2026 (GLOBE

    2/19/26 7:30:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CNSP
    $HLTH
    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Praxis Precision Medicines with a new price target

    Wolfe Research initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $500.00

    2/24/26 7:55:37 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $BLCM
    $CNSP
    $HLTH
    $KALA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BLCM
    $CNSP
    $HLTH
    $KALA
    Leadership Updates

    Live Leadership Updates

    View All

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $BLCM
    $CNSP
    $HLTH
    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CNSP
    $HLTH
    $KALA
    Financials

    Live finance-specific insights

    View All

    Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2

    3/4/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast

    2/18/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care